MedTech Forum 2019: The Future Is Here But Industry Still Needs A Long-Term Vision

In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.

Adapt
Time of change for medtech • Source: Shutterstock

If you want an insightful take on where the medtech industry should be headed, and what is required to get it to there, listen to Eric Thépaut. The Boston Scientific Corp. senior vice-president and president of the group’s EMEA region, sat down with In Vivo minutes after stepping off the stage at the MedTech Forum 2019 (Paris). There, he delivered an upbeat take on the changing businesses environment and expectations on medtech manufacturers, as well as their changing roles in an evolving health care sector.

Transformation and talent development have become twin passions for Thépaut (pictured) in a 22-year career at Boston Scientific. He is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.